Literature DB >> 20123448

Management of acute hepatitis C.

Anurag Maheshwari1, Paul J Thuluvath.   

Abstract

The World Health Organization estimates that about 170 million people are infected with hepatitis C virus (HCV). Blood transfusions from unscreened donors and unsafe therapeutic procedures are the major modes of HCV transmission in the developing world, and injection drug use accounts for most newly diagnosed HCV infections in the developed countries. Acute infection with HCV leads to symptomatic hepatitis in only a minority of patients, and recent studies suggest that spontaneous clearance of virus is higher in symptomatic acute hepatitis C infection. Pooled data from various studies suggest that higher sustained viral clearance rates could be achieved with a shorter course of antiviral treatment in the early stages of chronic HCV infection. This article examines the diagnosis of acute infection and critically appraises the various treatment regimens. (c) 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20123448     DOI: 10.1016/j.cld.2009.11.007

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  21 in total

1.  Making the best of a bad situation: early chronic nosocomial HCV infection.

Authors:  Carmi Santos; Steven K Herrine
Journal:  Dig Dis Sci       Date:  2010-05-18       Impact factor: 3.199

Review 2.  Host genetic basis for hepatitis C virus clearance: a role for blood collection centers.

Authors:  Suganya Selvarajah; Leslie H Tobler; Graham Simmons; Michael P Busch
Journal:  Curr Opin Hematol       Date:  2010-11       Impact factor: 3.284

Review 3.  Serodiagnosis for tumor viruses.

Authors:  Brian J Morrison; Nazzarena Labo; Wendell J Miley; Denise Whitby
Journal:  Semin Oncol       Date:  2014-12-31       Impact factor: 4.929

Review 4.  Hepatitis B and C.

Authors:  Wikrom Karnsakul; Kathleen B Schwarz
Journal:  Pediatr Clin North Am       Date:  2017-06       Impact factor: 3.278

5.  Effect of sofosbuvir and daclatasvir on lipid profile, glycemic control and quality of life index in chronic hepatitis C, genotype 3 patients.

Authors:  Ayush Jain; Bhupinder Singh Kalra; Siddharth Srivastava; Shalini Chawla
Journal:  Indian J Gastroenterol       Date:  2019-02-02

6.  Exploring small molecules with pan-genotypic inhibitory activities against hepatitis C virus NS3/4A serine protease.

Authors:  Jinhong Ren; Isabel Ojeda; Maulik Patel; Michael E Johnson; Hyun Lee
Journal:  Bioorg Med Chem Lett       Date:  2019-06-08       Impact factor: 2.823

Review 7.  Management of hepatitis C in patients with chronic kidney disease.

Authors:  Roberto J Carvalho-Filho; Ana Cristina C A Feldner; Antonio Eduardo B Silva; Maria Lucia G Ferraz
Journal:  World J Gastroenterol       Date:  2015-01-14       Impact factor: 5.742

8.  Unmet health care needs and hepatitis C infection among persons who inject drugs in Denver and Seattle, 2009.

Authors:  Alia A Al-Tayyib; Hanne Thiede; Richard D Burt; Stephen Koester
Journal:  Prev Sci       Date:  2015-02

Review 9.  Hepatitis C: is a vaccine the solution?

Authors:  Bharti Mehta; Vijay Kumar; Sumit Chawla; Harashish Jindal; Bhumika Bhatt
Journal:  Hum Vaccin Immunother       Date:  2013-10-28       Impact factor: 3.452

10.  Prevalence of hepatitis 'B' and hepatitis 'C' among preoperative cataract patients in Karachi.

Authors:  Syed Saad Naeem; Efaza Umar Siddiqui; Abdul Nafey Kazi; Sumaiyatauseeq Khan; Farhan E Abdullah; Idrees Adhi
Journal:  BMC Res Notes       Date:  2012-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.